192 related articles for article (PubMed ID: 26423701)
1. Direct Inhibitors of Ras-Effector Protein Interactions.
Upadhyaya P; Bedewy W; Pei D
Mini Rev Med Chem; 2016; 16(5):376-82. PubMed ID: 26423701
[TBL] [Abstract][Full Text] [Related]
2. Targeting Ras with Macromolecules.
Pei D; Chen K; Liao H
Cold Spring Harb Perspect Med; 2018 Mar; 8(3):. PubMed ID: 28778966
[TBL] [Abstract][Full Text] [Related]
3. Past, Present, and Future of Targeting Ras for Cancer Therapies.
Tan Z; Zhang S
Mini Rev Med Chem; 2016; 16(5):345-57. PubMed ID: 26423695
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides.
Upadhyaya P; Qian Z; Selner NG; Clippinger SR; Wu Z; Briesewitz R; Pei D
Angew Chem Int Ed Engl; 2015 Jun; 54(26):7602-6. PubMed ID: 25950772
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of Ras-SOS Interactions.
Lu S; Jang H; Zhang J; Nussinov R
ChemMedChem; 2016 Apr; 11(8):814-21. PubMed ID: 26630662
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule modulation of Ras signaling.
Spiegel J; Cromm PM; Zimmermann G; Grossmann TN; Waldmann H
Nat Chem Biol; 2014 Aug; 10(8):613-22. PubMed ID: 24929527
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of RAS: New hope for drugging the "undruggable".
Khan I; Rhett JM; O'Bryan JP
Biochim Biophys Acta Mol Cell Res; 2020 Feb; 1867(2):118570. PubMed ID: 31678118
[TBL] [Abstract][Full Text] [Related]
8. Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.
Wang Y; Kaiser CE; Frett B; Li HY
J Med Chem; 2013 Jul; 56(13):5219-30. PubMed ID: 23566315
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides.
Trinh TB; Upadhyaya P; Qian Z; Pei D
ACS Comb Sci; 2016 Jan; 18(1):75-85. PubMed ID: 26645887
[TBL] [Abstract][Full Text] [Related]
10. K-Ras protein as a drug target.
McCormick F
J Mol Med (Berl); 2016 Mar; 94(3):253-8. PubMed ID: 26960760
[TBL] [Abstract][Full Text] [Related]
11. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
12. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
Huynh MV; Campbell SL
Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
[TBL] [Abstract][Full Text] [Related]
13. The renewed battle against RAS-mutant cancers.
Zhang F; Cheong JK
Cell Mol Life Sci; 2016 May; 73(9):1845-58. PubMed ID: 26892781
[TBL] [Abstract][Full Text] [Related]
14. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract][Full Text] [Related]
15. Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras.
Shi M; Zheng Y; Garcia A; Xu L; Foster DA
Cancer Lett; 2007 Dec; 258(2):268-75. PubMed ID: 17949898
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of the KRAS-PDK1 axis in pancreatic cancer.
Ferro R; Falasca M
World J Gastroenterol; 2014 Aug; 20(31):10752-7. PubMed ID: 25152578
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of the ERK mitogen-activated protein kinase cascade for targeting RAS mutant cancers.
Gentry L; Samatar AA; Der CJ
Enzymes; 2013; 34 Pt. B():67-106. PubMed ID: 25034101
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
Ihle NT; Lemos R; Wipf P; Yacoub A; Mitchell C; Siwak D; Mills GB; Dent P; Kirkpatrick DL; Powis G
Cancer Res; 2009 Jan; 69(1):143-50. PubMed ID: 19117997
[TBL] [Abstract][Full Text] [Related]
20. Conformation-specific inhibitors of activated Ras GTPases reveal limited Ras dependency of patient-derived cancer organoids.
Wiechmann S; Maisonneuve P; Grebbin BM; Hoffmeister M; Kaulich M; Clevers H; Rajalingam K; Kurinov I; Farin HF; Sicheri F; Ernst A
J Biol Chem; 2020 Apr; 295(14):4526-4540. PubMed ID: 32086379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
